We will make headway into the global market beyond the domestic market by gathering the ability of JW.
-Participating in the 'World Orphan Drug Congress USA 2026' in Boston from June 9 to 11-Unveil...
-Multinational Phase 3 trials conducted across five Asian countries, including South Korea-Eva...
-Secures exclusive domestic rights for the development and commercialization of the diabetes and obe...
-A GFRA1 receptor agonist and First-in-Class topical novel drug candidate-Phase 1 IND approved...
-Secures exclusivity until 2039… Demonstrating the competitiveness of its proprietary technolo...
-First-in-Class drug candidate discovered utilizing the proprietary ‘JWave’ platform-Accelerat...
-Exclusivity period extended to 2038… accelerating the development of a global Best-in-Class g...
-AI-based small molecule drug research recognized as a national R&D project-Direct STAT6 i...
• First-in-Class oral dual inhibitor targeting STAT5/STAT3• Discovered through JW’s AI-based integra...
-First domestic partnership with Tempus AI, the world’s largest holder of clinical and genomic...